Highlights from ILCA and ESMO 2021 in HCC

Episode 2 September 30, 2021 00:13:19
Highlights from ILCA and ESMO 2021 in HCC
COR2ED Medical Education
Highlights from ILCA and ESMO 2021 in HCC

Sep 30 2021 | 00:13:19

/

Show Notes

Professor Matthias Pinter, medical hepatologist from the medical University of Vienna in Austria shares some insights from key abstracts and topics discussed at ILCA 2021 and ESMO 2021 in hepatocellular carcinoma.

One main topic included discussions about treatment options in first-line systemic therapy and managing patients who still may need to receive a TKI in first-line instead. Another topic covered is how to proceed with immunotherapy in HCC, in particular the rationale for triplet immunotherapy combination.

There were two studies data presented on atezolizumab plus bevacizumab, the new reference standard of care in systemic front-line HCC treatment.

Another interesting topic was the combination of TACE with immune checkpoint blockade in intermediate stage HCC.

Regarding monotherapy TKI in first-line setting, Prof Pinter points out that around 15 to 20% of HCC patients are not ideal candidates for atezolizumab plus bevacizumab, and these are mainly patients with HCC recurrence of the liver transplantations, patients with severe autoimmune disease, or those with a high bleeding risk.

He discusses several real-world evidence studies including lenvatinib, sorafenib and regorafenib in special populations that are usually excluded from clinical trials.

 Prof Pinter also discusses data presented covering predictive and prognostic biomarkers such as cachexia, the growing role of AI, multibipolar radiofrequency ablation and the potential role of underlying etiology as a predictor of the efficacy of immunotherapy.

Other Episodes

Episode

November 29, 2023 00:27:39
Episode Cover

Gene therapy and gene-modified cell therapy in rare diseases

Gene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their...

Listen

Episode 2

October 03, 2021 00:16:30
Episode Cover

ASBMR 2021 Rare Bone Disease Highlights from Day Two

We have partnered with international experts to provide rare bone diseases highlights from ASBMR 2021. This is the second in a series of four...

Listen

Episode 15

June 29, 2023 00:22:50
Episode Cover

PBC Highlights from EASL 2023 – episode 2

COR2ED Medical Education: Robert Mitchell-Thain, CEO of the PBC Foundation, Edinburgh, UK and Kath Houghton, Autoimmune Specialist Nurse, Newcastle upon Tyne Hospitals NHS Foundation...

Listen